BeyondSpring Inc. (BYSI)
NASDAQ: BYSIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BYSI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $13.66M
- EPS (TTM)
- -$0.20
- Dividend yield
- None
- 52-week range
- 0.299 – 2.44
- Day range
- 0.3164 – 0.4554
- Volume / Avg
- 70.95K / 261.79K
- Beta
- —
- Shares outstanding
- 41.41M
52-week range
BYSI stock today
On Nov 20, BYSI ended the session at $0.33, shedding $0.107 (24.49%), versus the S&P 500's 3.70% decline. Trading was light, with 70.95K shares changing hands, about 27% of the average daily volume. Shares are 86.5% below their 52-week high of $2.44, set on Dec 12, 2025 and 10.4% above the 52-week low of $0.299, near the bottom of the past year's range.
BYSI is down 79.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 82.8%. BeyondSpring has posted a net loss over the last twelve months (EPS of -$0.20), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About BeyondSpring
Company profileBeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Min Qiu
- Headquarters
- Florham Park, NJ
- Employees
- 44
- IPO year
- 2017
- Website
- beyondspringpharma.com
Financial highlights
Full financialsIn fiscal 2025, BeyondSpring generated $0 in revenue, up 0.0% from fiscal 2024. BeyondSpring reported a net loss of $1.0 million, compared with a loss of $11.1 million a year earlier.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1.35M | $1.35M |
| Growth | — | — | -100.00% | 0.00% | +650.56% |
| Net income | $-1.01M | $-11.12M | $-21.03M | $-33.28M | $-64.18M |
| EPS (diluted) | — | — | — | — | $-1.64 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.05 vs —
BYSI news
All BYSI newsBeyondSpring peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ACTUActuate Therapeutics Inc. | 0.2253 | +5.38% | $13.60M | vs BYSI |
| CTXRCitius Pharmaceuticals Inc. | 0.5085 | +2.27% | $13.96M | vs BYSI |
| TVRDTvardi Therapeutics Inc. | 0.9893 | +4.57% | $13.22M | vs BYSI |
| BOLTBolt Biotherapeutics Inc. | 4.91 | -2.96% | $12.80M | vs BYSI |
| NEUPNeuphoria Therapeutics Inc. | 2.35 | +1.29% | $12.72M | vs BYSI |
| NCELNewcelX Ltd. | 2.54 | -5.58% | $14.67M | vs BYSI |
| MCRBSeres Therapeutics Inc. | 1.24 | -6.77% | $12.64M | vs BYSI |
| CNTXContext Therapeutics Inc. | 0.16 | -5.10% | $14.70M | vs BYSI |
Indexes, lists and sector
BeyondSpring stock FAQ
What is BeyondSpring's stock price today?
BYSI last traded at $0.33 as of Nov 20, 4:00 PM EST, down 24.49% on the day. Prices are delayed at least 15 minutes.
Who is BeyondSpring's CEO?
Mr. Min Qiu is the chief executive officer of BeyondSpring Inc., which has about 44 employees.
What is the BYSI 52-week high?
The 52-week high for BYSI is $2.44 and the 52-week low is $0.299. The stock is currently 86.5% below its high.